Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Affirm Holdings Inc (AFRM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance

Affirm Holdings IncTrade
State Street SPDR S&P Biotech ETFTrade

Price performance (Past 24H)

Key statistics

Affirm Holdings Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Affirm Holdings Inc trades at $76.91 (market cap $25.30B), while State Street SPDR S&P Biotech ETF trades at $158.06. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Affirm Holdings Inc nearer its low. Which is the better fit depends on your goals.

AFRMXBI
Market Cap
$25.30B
Sector
FinancialsBroad Market / Factor
52-Week High
$92.18$164.28
52-Week Low
$42.53$86.92
Enterprise Value
$31.91B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Affirm Holdings Inc

AFRM trades at $75.25, down 1.74% on the day, with a bullish technical signal supported by moving averages. The company reported strong revenue growth to $3.22B in 2025, turning profitable with net income of $52.19M, and has beaten EPS estimates in recent quarters. Positive sentiment is driven by analyst optimism and expanding merchant partnerships.

Outlook remains favorable with a consensus price target of $96.00, indicating 28% upside. Risks include high valuation multiples (P/E 68.41) and sensitivity to interest rate changes. Continued execution on growth and profitability will be key for stock performance.

State Street SPDR S&P Biotech ETF

XBI, the SPDR S&P Biotech ETF, trades at $157.37, up 1.88% today, with a bullish technical signal from moving averages and strong momentum indicators. The ETF has surged nearly 17% in a month, driven by positive clinical trial news and increased M&A activity in the biotech sector. Analyst coverage is limited to one hold rating, reflecting cautious optimism amid high volatility.

Outlook remains positive due to sector tailwinds like AI-driven drug discovery and robust M&A, but risks include policy uncertainty and the fund's high beta. Investors should weigh the potential for continued growth against inherent volatility in small- and mid-cap biotech holdings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Affirm Holdings Inc

Affirm Holdings Inc offers a platform for digital and mobile first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a major share of its revenue from the United States.

Read more on AFRM

About State Street SPDR S&P Biotech ETF

XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.

Read more on XBI